Recently, thelaunching ceremony of Phase I clinical trialsof innovative injectable anti-tumor drugs of class 1.1- HYD-PEP06, has been held in form of a videoconference in Guangzhou, Zhuhai, Harbin at the same time. This conference marksthat HYD-PEP06 officially entered the phase Ⅰ clinicaltrial stage.
HYD-PEP06 is the research achievement of Professor Baofeng Yang, anacademician of the Chinese Academy of Engineering and former president ofHarbin Medical University. Ruihua Xu ,Director of Sun Yat-sen Cancer Hospital , is responsible for the clinicalresearch of the project as PI. And Guangzhou Boji Medical biotechnologicalco.,Ltd provides full-scaleCRO services for this Phase I clinical trials .
